EGFR and esophageal squamous cell carcinoma: Gefitinib is a common chemotherapy choice for patients with ESSC.17 The previous study has revealed that gefitinib could sensitize mutations in ESCC to chemotherapy treatment.18 Mechanism research has identified that gefitinib could sensitize mutation in ESCC cell line KYSE450 via EGFR.19 However, a phase II study about gefitinib in treating ESCC showed that although the overall response rate could reach 90%, the complete response was only 40% and median progression‐free survival was 7.0 months,7 suggesting there might be a large room to improve this treatment.